Dr. Tammy Clifford is the Vice-President, Strategic Initiatives, and Chief Scientist at the Canadian Agency for Drugs and Technologies in Health (CADTH). Her responsibilities include aligning with best practices the methods and processes employed in conducting assessments on drugs and other health technologies, assuring the continued quality of CADTH reports, and building capacity amongst producers and users of evidence-based assessments by providing education, training, and outreach. Dr. Clifford holds faculty appointments in Pediatrics and in Epidemiology and Community Medicine at the University of Ottawa. Dr. Clifford received her PhD in Epidemiology and Biostatistics from the University of Western Ontario and both her BSc and MSc(A) from McGill University. Tammy is known for her research on infant colic and also studies the methods underpinning systematic reviews. She has a keen interest in the editorial peer review process.
Barry Jones graduated with a Pharmacy degree at the University of London, UK. He spent several years as the Chief Pharmacist for Phoenix Group Pharmacies in Bermuda, before operating a successful Pharmacy business there. He is a former president of the Bermuda Pharmaceutical Association. Since returning to Canada with his family, Barry has been employed with Health Canada and has worked in areas of pre-market activities, post-market surveillance and controlled substances. Presently, Barry is with the office of Pharmaceutical Management Strategies (OPMS) within Strategic policy Branch (SPB). He is acting Associate Director and a Senior Policy Analyst. His areas of expertise include expensive drugs for rare diseases (orphan drugs), personalised medicine (and targeted therapies), pricing of pharmaceuticals and market access strategies.
In his current role within Pharmaceutical Services Division, Ministry of Health Services, Eric leads the Drug Intelligence branch. The branch consists of several operating units including Formulary Management, Special Authority, Clinical Decision Support, and the Alzheimer’s Drug Therapy Initiative. Formulary Management is responsible for the PharmaCare drug review process and benefit listing decisions while the Special Authority program is responsible for adjudicating requests for limited coverage drugs. Prior to joining PSD, Eric worked with the Vancouver Coastal Health Authority as Regional Coordinator, Medication Use Management, responsible for managing the Health Authority’s drug formulary. Eric has also worked as a financial research analyst for the biotech and healthcare sector (TD Securities), as a clinical pharmacist (Vancouver General Hospital), a Drug Use Evaluation pharmacist (University of Alberta Hospital), and a pharmacy lecturer (University of Technology, Jamaica).
Bob Nakagawa is Registrar of the College of Pharmacists of British Columbia. Prior to joining the College as Registrar in April 2012, Bob was the Assistant Deputy Minister of the Pharmaceutical Services Division of the Ministry of Health.
Bob has a pharmacy degree from UBC and a residency in hospital pharmacy from St. Paul’s Hospital in Vancouver and is a Fellow of the Canadian Society of Hospital Pharmacists. He has worked both in hospital and in government in developing innovative services and policies for the last 3 decades. He has served as President of the College of Pharmacists of BC, as well as the Canadian Society of Hospital Pharmacists.
Bob is an expert in public drug plan management and has provided advice to federal, provincial and international governments in this area. Bob has chaired the Drug Benefits Committee for BC PharmaCare and the Federal Pharmacy and Therapeutics Committee for Canada.